Michael Parini Net Worth

The estimated Net Worth of Michael Parini is at least $44.4 Milión dollars as of 24 February 2021. Mr. Parini owns over 3,028 units of Vertex Pharmaceuticals stock worth over $14,639,557 and over the last 9 years he sold VRTX stock worth over $24,340,079. In addition, he makes $5,372,340 as Executive Vice President a Chief Legal and Administrative Officer at Vertex Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Parini VRTX stock SEC Form 4 insiders trading

Michael has made over 61 trades of the Vertex Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 3,028 units of VRTX stock worth $646,115 on 24 February 2021.

The largest trade he's ever made was selling 40,764 units of Vertex Pharmaceuticals stock on 25 April 2018 worth over $6,493,298. On average, Michael trades about 3,572 units every 22 days since 2016. As of 24 February 2021 he still owns at least 30,837 units of Vertex Pharmaceuticals stock.

You can see the complete history of Mr. Parini stock trades at the bottom of the page.

Michael Parini biography

Michael J. Parini, J.D. is Executive Vice President, Chief Legal and Administrative Officer of the Vertex Pharmaceuticals Incorporated since January 2017. From January 2016 to January 2017, he was our Executive Vice President and Chief Legal Officer. From 2004 until he joined Vertex, Mr. Parini served in various roles of increasing responsibility at Pfizer Inc., a pharmaceutical company, most recently as Senior Vice President and Associate General Counsel. Prior to Pfizer, Mr. Parini was an attorney at Akin, Gump, Strauss, Hauer & Feld, L.L.P. Mr. Parini holds a B.A. from Georgetown University and a J.D. from the Georgetown University Law Center.

What is the salary of Michael Parini?

As the Executive Vice President a Chief Legal and Administrative Officer of Vertex Pharmaceuticals, the total compensation of Michael Parini at Vertex Pharmaceuticals is $5,372,340. There are 5 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.

How old is Michael Parini?

Michael Parini is 44, he's been the Executive Vice President a Chief Legal and Administrative Officer of Vertex Pharmaceuticals since 2017. There are 24 older and no younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.

What's Michael Parini's mailing address?

Michael's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.

Insiders trading at Vertex Pharmaceuticals

Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden a Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

Complete history of Mr. Parini stock trades at Vertex Pharmaceuticals

Vertex Pharmaceuticals executives and stock owners

Vertex Pharmaceuticals executives and other stock owners filed with the SEC include:

• Jeffrey Leiden,
  Executive Chairman of the Board
• Stuart Arbuckle,
  Executive Vice President, Chief Commercial Officer
• Reshma Kewalramani,
  President, Chief Executive Officer, Director
• Amit Sachdev,
  Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
• David Altshuler,
  Executive Vice President - Global Research, Chief Scientific Officer
• Michael Parini,
  Executive Vice President, Chief Legal and Administrative Officer
• Dr. Reshma Kewalramani FASN, M.D.,
  CEO, Pres & Director
• Charles Wagner,
  Chief Financial Officer, Executive Vice President
• Paul Silva,
  Senior Vice President, Controller
• Dr. Jeffrey Marc Leiden M.D., Ph.D.,
  Exec. Chairman
• Stuart A. Arbuckle B.Sc.,
  Exec. VP & COO
• Dr. David M. Altshuler,
  Exec. VP of Global Research & Chief Scientific Officer
• Charles F. Wagner Jr.,
  Exec. VP & CFO
• Bruce Sachs,
  Co-Lead Independent Director
• Margaret McGlynn,
  Independent Director
• Terrence Kearney,
  Independent Director
• Sangeeta Bhatia,
  Independent Director
• Yuchun Lee,
  Independent Director
• William Young,
  Independent Director
• Alan Garber,
  Independent Director
• lloyd Carney,
  Independent Director
• Michael Partridge,
  Vice President - Investor Relations
• Diana McKenzie,
  Independent Director
• Nia Tatsis,
  Senior Vice President, Chief Regulatory Officer
• John Gray,
  Senior Vice President, Genetic Therapies
• Gerald Bruce,
  Executive Vice President, Commercial Operations
• Carmen Bozic,
  Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
• Joy Liu,
  Sr. VP & Gen. Counsel
• Damian W. Wilmot Esq.,
  Sr. VP, Chief Risk and Compliance Officer
• Mike Tirozzi,
  SVP and Chief Information & Data Officer
• Kristen Ambrose,
  Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services
• Joshua S Boger,
  Chairman & CEO
• Elaine Ullian,
  Director
• Ian F Smith,
  SVP & CFO
• Jeffrey Chodakewitz,
  SVP GMDA, CMO
• Thomas Graney,
  Chief Financial Officer
• Michel Lagarde,
  Director
• Wayne Joseph Riley,
  Director
• Peter Mueller,
  CSO & SVP Drug Discovery
• Thomas Connolly,
  SVP, Human Resources
• Kenneth L Horton,
  EVP & Chief Legal Officer
• Megan E Pace,
  SVP, Corp. Communications
• Christiana Stamoulis,
  SVP, Corp Strategy & Bus Devlp
• Matthew Emmens,
  Director
• Lisa Kelly,
  SVP, Human Resources
• Dennis L Winger,
  Director
• Eugene Cordes,
  Director
• Nancy Wysenski,
  EVP & Chief Commercial Officer
• David T Howton,
  SVP
• Kenneth S Boger,
  SVP & General Counsel
• Kurt Graves,
  EVP, Chief Commercial Officer
• John J Alam,
  SVP, Drug Eval. & Appr.
• Stuart J Collinson,
  Director
• Charles A Sanders,
  Director
• Roger W Brimblecombe,
  Director
• Freda C Lewis Hall,
  EVP, Medicines Development
• Eve Elizabeth Slater,
  Director
• Richard C Garrison,
  SVP, Organizational Developmen
• Johanna Messina Power,
  Controller
• Victor A Hartmann,
  EVP, Strategic & Corp. Devlp.
• Eric Brandt,
  Director
• Lynne H Brum,
  VP, Corp. Comm.&Financial Plan
• Paul A Negulescu,
  VP, Research
• John F Niblack,
  Director
• Iain P M Buchanan,
  VP, European Operations
• Vicki L Sato,
  President
• N Anthony Coles,
  SVP, Comm. Ops.
• Bastiano Sanna,
  EVP, Cell & Genetic Therapies
• Joy Liu,
  SVP, General Counsel
• Kristen Ambrose,
  SVP & Chief Accounting Officer
• Suketu Upadhyay,
  Director
• Jonathan Biller,
  EVP and Chief Legal Officer
• Nancy Thornberry,
  Director
• Edward Morrow Iii Atkinson,
  EVP, Chief Technical Ops. Off.
• Jennifer Schneider,
  Director